MGL-3196 80 mg oral, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 60 mg film-coated tablet, MGL-3196 60 mg oral, MGL-3196 100 mg oral, Matching placebo MGL-3196 100 mg film-coated tablet
MGL-3196-19
Phase 3 small_molecule active
Quick answer
MGL-3196 80 mg oral, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 60 mg film-coated tablet, MGL-3196 60 mg oral, MGL-3196 100 mg oral, Matching placebo MGL-3196 100 mg film-coated tablet for Non-alcoholic Steatohepatitis (NASH) Cirrhosis is a Phase 3 program (small_molecule) at Madrigal Pharmaceuticals EU Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Madrigal Pharmaceuticals EU Limited
- Indication
- Non-alcoholic Steatohepatitis (NASH) Cirrhosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active